Oncologic markers in patients with colorectal cancer after a complex therapy.
The authors present a prospective study on a value of oncologic markers CEA and CA 19-9 in patients after curative therapy for colorectal adenocarcinoma. During a five-year follow-up in 320 patients, a significant elevation of CEA or CA 19-9 was documented in 71 patients (22.8 %), and resulted in tumour detection in 39/71 patients (55 %). Although the levels were defined as false positive in 32 patients (45 %), the importance of CEA and CA 19-9 monitoring is documented by elevated levels of oncomakers in 39/55 patients (71%) with metastases or local-regional recurrence of colorectal adenocarcinoma. (Tab. 3, Ref: 21.)
Vyslouzil
K
K
2nd Department of Surgery, University Hospital and Faculty of Medicine, Palacky University, Olomouc, Czech Republic. bll@fmed.uniba.sk
Klementa
I
I
Stary
L
L
Duda
M
M
Skalicky
P
P
Kapustova
M
M
Dlouhy
M
M
Benes
P
P
D018395:CA-19-9 Antigen / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D015179:Colorectal Neoplasms / Q000097:blood / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000556:secondary; D008175:Lung Neoplasms / Q000175:diagnosis / Q000556:secondary; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis
D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen